Staidson announced that its profit in the first half of 2016 reached 100 million yuan, an increase of 10 percent from the previous year.

Staidson will use 100 million yuan to extend manufacturing facilities for freeze-dried powder injection and solid injection, and will buy 67 pieces of production equipment. It will produce 23 million bottles of Mouse Nerve Factor Injection and 30 million boxes of SF-PEG in the future.

The sales volume of Mouse Nerve Factor Injection and SF-PEG rose 20.13 percent and 18.86 percent respectively in 2015 over the previous year. To meet the demands of the market, the manufacturing shop will be extended. A challenge for Staidson Biopharmaceuticals Company is to raise its automation level to make production less labor intensive.